A cancer/testis antigen microarray to screen autoantibody biomarkers of non-small cell lung cancer
A cancer/testis antigen microarray to screen autoantibody biomarkers of non-small cell lung cancer
复制标题
用于筛选非小细胞肺癌自身抗体生物标志物的癌症/睾丸抗原微阵列
DOI：
10.1016/j.canlet.2012.08.019
复制
发表时间：
2013-01-01
期刊：
影响因子：
9.7
通讯作者：
Liu, Siqi
中科院分区：
文献类型：
--
作者：
Shan, Qiang;Lou, Xiaomin;Liu, Siqi
癌症/睾丸抗原（CTA）在许多肿瘤中具有高度免疫原性，特别是在非小细胞肺癌（NSCLC）中。采用低密度蛋白质微阵列技术，包括72个CTA和6个非CTA，用于筛选肺癌相关自身抗体。NY-ESO-1、XAGE-1、ADAM 29和MAGEC 1的CIA组的敏感性和特异性值分别为33%和96%。当在测试集中检查时，该组标志物的灵敏度和特异性值分别为36%和89%。这一系列标志物优先检测NSCLC，但不能检测乳腺癌和非癌性肺病。(C)2012爱思唯尔爱尔兰有限公司保留所有权利。
Cancer/testis antigens (CTAs) are highly immunogenic in many tumors, especially in non-small cell lung cancer (NSCLC). A low-density protein microarray, which consisted of 72 CTAs and six non-CTAs, was used to screen for lung cancer-related autoantibodies. The CIA panel of NY-ESO-1, XAGE-1, ADAM29 and MAGEC1, had sensitivity and specificity values of 33% and 96%, respectively. When examined in a test set, this panel of markers had sensitivity and specificity values of 36% and 89%, respectively. This array of markers preferentially detected NSCLC, but did not detect breast cancer, and non-cancer lung disease. (C) 2012 Elsevier Ireland Ltd. All rights reserved.